GOCOVRI
What it isExtended-release NMDA antagonist with incompletely defined dopaminergic effects for levodopa dyskinesia and off episodes (GOCOVRI, 2017).
Why this oneIts bedtime dosing yields high morning levels, and it is the only drug labeled for levodopa-induced dyskinesia in Parkinson disease.
What limits itRenal accumulation causes confusion and hallucinations; livedo reticularis, edema, and orthostasis also limit use.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Parkinson's disease dyskinesia (on levodopa) | Adults | 137 mg QHS | 274 mg QHS | 274 mg QHS |
| Parkinson's disease 'off' episodes (adjunct to levodopa/carbidopa) | Adults | 137 mg QHS | 274 mg QHS | 274 mg QHS |
Titration Increase after 1 week
Renal Moderate (CrCl 30-59): 68.5 mg QHS, max 137 mg QHS; Severe (15-29): 68.5 mg QHS; ESRD (<15): contraindicated
Hepatic Undefined
Contraindicated in end-stage renal disease
Pregnancy Based on animal data, may cause fetal harm; no adequate human data
Lactation Amantadine excreted in human milk (amounts not quantified); may alter milk production
NO BOXED WARNINGS
Principal riskLivedo reticularis; confusion in renal impairment

Open Amantadine ER in the interactive console ↗

